Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Lupin’s world class manufacturing facilities are spread across India, USA, Mexico and Brazil.
These 15 facilities benchmarked to international standards are set up to meet stringent quality standards, playing a critical role in achieving our global growth aspirations.
All our facilities are approved by international regulatory agencies like US FDA, UK MHRA, TGA Australia, WHO, and the MCC South Africa.
Research and Development (R&D) forms an integral part of our business strategy. With research and development sites across the globe, our recent R&D endeavour have led to significant progress in many areas including New Chemical Entity (NCE) program. Additionally, our foray into the Advanced Drug Delivery Systems (ADDS) has resulted in platform technologies that are used to develop value-added generic pharmaceuticals.
Lupin is headquartered in Mumbai (India). It is listed on the National Stock Exchange (NSE) as well as the Bombay Stock Exchange (BSE) and has a presence on the Bloomberg and Reuters terminals.
With a patient-first approach, Lupin is transforming the pharmaceutical industry to find novel ways of utilizing technology and research to focus on high-quality and affordable medicines, not just for few but to many across the globe.
What started as one man’s journey and his belief in the virtue of his cause, has paved the path for Lupin to become a global pharmaceutical major.
Lupin began as one man’s dream of creating a better world. Dr. Desh Bandhu Gupta, lovingly known as DBG, believed in the idea of ‘simple living and high thinking’ and aspired to put India on the global pharmaceuticals map. DBG’s legacy is one of performance, values and public spiritedness. At 50, Lupin is a strong and vast fabric woven in his strong values adopted by the passionate team of professionals working to offer medicines and researching through our global web of laboratories to build and grow in the world of pharmaceuticals.
When Dr. Gupta started Lupin in 1968, his wife, Mrs. Manju Gupta, served as his first investor with an investment of INR 5,000. To DBG, Lupin was a weapon to fight life-threatening diseases that plagued his nation. Today, Lupin has successful operations in over 100 countries and it is largely because of the culture of innovation, unyielding integrity, and world-class operations that DBG pioneered. But DBG’s true genius as an entrepreneur lay in bringing out the best in every person he met.
Business to him was sacred and he operated with the highest ethical standards, professionalism and respect.
Over the past 50 years, with DBG at the helm of affairs, Lupin saw both struggles and victories. But his personality encouraged learning from the experiences and never rest on laurels. He inspired the team to move ahead, set high targets and meet one’s goals through unyielding commitment to compliance and integrity. He had a compelling vision of the future and strived to light the path of glory.
As we look forward to our altruistic heritage as a world leader, DBG’s vision guides us. He often stated, “Dreaming big is not enough, you must convert these dreams into real actionable plans. You must challenge yourself to seek excellence and to innovate; to continuously connect vision, strategy and execution. That is what makes a company great and go beyond mere growth”.
Of all the hats, he wore in his lifetime, DBG was most happy to have contributed to creating a more inclusive society – one that provides opportunities to all who need them. He was always proud of being an Indian who contributed to the nation-building process.
Lupin has navigated the market without losing sight of his vision. As we look to our 50 year’s journey, we continue to be inspired by DBG’s guiding tenets: to focus on research to be a growth driver; to make technology a differentiator to achieve world-class manufacturing standards; to focus on quality; make people our strength – bringing and retaining the right people on board, giving them autonomy and enabling them to succeed; caring for people and all our stakeholders; always focus on affordable high-quality healthcare, especially in areas of unmet needs.
Today, we are truly a multinational pharmaceutical company focused on meaningful and differentiated product portfolio comprising of Complex Generics, Biosimilars and Specialty Products. As we continue the journey started in 1968, we commit to the legacy that is our honour to uphold.
Embedded in Lupin is a formula for growth...the future looks brighter than it has ever been.
Embedded in Lupin is a formula for growth. We are ‘Built to Grow’.
Fifty years on, what has stayed with us is the same entrepreneurial spirit, culture of creativity & innovation and we pride in belonging to an industry which makes a difference in the lives of people. Today, we are a fully integrated pharmaceutical company with an unrivalled position in the US, India and Japan. This position is built on a backbone of cutting-edge research, world-class manufacturing facilities and a truly global supply chain. With these building blocks in place, the future looks brighter than it has ever been.